Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Neuroblastoma 1Neoplasm Metastasis 1Medulloblastoma 1Liver Neoplasms 1Hepatoblastoma 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Fibrosis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Neoplasms 1Basal Cell Nevus Syndrome 1Astrocytoma 1

Interventions

Gemcitabine 8130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 2Paclitaxel 2MK-4721 2Irinotecan 2Blood Specimen Collection 2sonidegib 1parecoxib 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1copper dotatate CU-64 1Taxes 1Surveys and Questionnaires 1Sunitinib 1Rehabilitation 1Postoperative Care 1Piperacillin, Tazobactam Drug Combination 1Oxaliplatin 1Ocoxin 1Needles 1Methods 1Lutetium-177 1Lutetium 1Leucovorin 1Histocompatibility Testing 1HhAntag691 1Fluorouracil 1Duodenoscopes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Diseases × sonidegib × Gastrointestinal × Clear all
NCT01431794 2020-01-22

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Terminated
23 enrolled 10 charts
Gastrointestinal

Carcinoma, Pancreatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡